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ABSTRACT: Diabetic nephropathy is the kidney disease that occurs as a result of diabetes. Cardiovascular and 
renal complications share common risk factors such as blood pressure, blood lipids, and glycemic control. The 
markers of diabetics nephropathy in diabetic patients, serum glucose, creatinine clearance, urinary albumin and 
blood pressure in 40 diabetic (9 type I and 31 type II diabetics) patients attending Federal Medical Centre, Gusau, 
were determined. Sixteen (16) age- matched volunteers served as control. In type I diabetes mellitus; serum 
glucose level, creatinine clearance, and microalbuminuria were significantly different (P< 0.05) between the subjects 
and control. In type II diabetes mellitus, serum glucose level, systolic pressure and age were significantly different 
(P< 0.05) between the subjects and control. Therefore, serum glucose level, creatinine Clearance and 
microalbuminuria could be the markers of nephropathy in type I diabetics while serum glucose level, systolic 
pressure and higher age could be for type II diabetics. Other markers of risk for diabetic nephropathy are needed for 
optimal clinical management. The implication of this result for improving the quality of life of diabetics is discussed. 
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INTRODUCTION 
Diabetic nephropathy, a leading course of kidney failure 
and one of the key complications of diabetics, is defined 
by either microalbuminuria that is a urinary albumin 
excretion greater that 300mg in a 24 hour collection or 
by abnormal renal function as present by an 
abnormality in serum creatinine, calculated creatinine 
clearances or glomerular filtration rate (GFR) in diabetic 
patients (Amos et al., 1997).  
 
Diabetics kidney disease is one of the most common 
cause of end stage kidney disease (ESKD) and account 
for a large proportion of patients beginning dialysis 
therapy (USSRDS 2001). Up until two decades ago 
diabetes mellitus was reported to be an uncommon 
cause of chronic kidney disease in Nigeria (Oyediran 
and Akinkugbe 1970). But in the last few years, reports 
from several Renal units in the country now place 
diabetic nephropathy as a third most common causes 
of chronic renal failure (Sanusi et al., 1979). 
Microalbuminuria, glomerularhyperfiltration, and 
hypertension are markers for renal events  in diabetes 
and their presence predict development of clinical 
diabetics nephropathy (Ravid and Brosh 1998). 
Diabetics nephropathy or diabetics kidney disease, 
affects 20 to 30 percent of patients with diabetes, it is 
also common cause of kidney failure (Navarro et al., 
2003) 
 
Diabetic nephropathy presents in its earliest stage with 
low level of albumin (microalbuminuria) in the urine, this 
often is referred to as incipient nephropathy. As the 
disease progress, urine albumin levels increase until 
the patient develops overt nephropathy (define as more 
than 300mg per 24 hours or more than 200mcg per 
minute). Overt nephropathy occurs in conjugation with 
hyperfiltrative period in which creatinine clearance and 
glomerular filtration rate are high (USRDS 2002). The 
elevated clearance is deceptive, however, because it is 
fllowed by a gradual decrease in glomerular filtration 
rate that ultimately leads to kidney failure (Gal et al., 
1997) 
 
MATERIALS AND METHODS 
Patients Recruitment and Collection of Samples 
The study area is Gusau, Zamfara State, Nigeria. Blood 
and urine samples were collected and weight, height 
and blood pressure were measured in diabetic patients 
attending Federal Medical Centre, Gusau, Zamfara 
state. Samples from healthy volunteers were used as 
control. 
 
All subjects were instructed to fast for 12 hours after 
which 4ml venous blood samples were obtained by 
venipucture and urine samples were collected in fresh 
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were immediately taken. Serum from the blood 
obtained and urine were used for analysis.  
 
Chemicals, Reagents, and Equipment 
Glucose and Creatinine Reagent kits ware purchased 
from Randox laboratories ltd, Diamond road, crumlin 
co, Atrim,, United Kingdom. All chemicals and reagents 
used were of analytical grade. General laboratory 
routine equipment were used. 
 
Serum Glucose Determination 
Enzymatic determination of glucose concentration was 
done using glucose oxidase method according to 
Trinder (1969). 
 
Determination of Creatinin 
Jaffe’s creatinine reaction method by Jaffe’s (1886) was 
used in the determination of creatinine and then 
cockroft Goult formular (cockroft 1976) was used to 
calculate creatinine clearance. 
  
Determination of Albumin 
Urine albumin determination was by Strip Method 
(Boehringer Mannhein), which is based on the “Protein 
error” principles of indicators 
 
Statistical Analysis 
The result is presented as mean+ standard deviation. 
Significant differences between means were compared 
using SPSS application package. 
 
RESULTS AND DISCUSSION  
The results of demographic and some physicochemical 
characteristic in diabetes and control subjects are 
presented in Table 1.  
 
 
Table 1: Demographic and some Physicochemical Characteristic in Diabetes and Control Subjects 
Parameters  Type I diabetics Type II  diabetics Control 
No of subjects 9 31 16 
Age (years) 32.667 ± 3.391 (35-39) 55.709 ± 9.082 (45-74) 40.375±14.532 (24-65) 
weight (kg) 57.667±7.55 69.58 ±17.117 63.562± 3.076 
Systolic Pressure (mmHg) 140±26.458 137.807±21.162 122.652±17.988 
Diastolic pressure (mmHg) 86.66± 18.708 85± 13.354 78.125 ± 11.087 
FBS (mmol) 10.489±4.901 8.719± 4.368 4.856±1.022* 
CCL(mls/min) 63.914± 20.667 71.747± 30.02 82.703±17.864 
Microalbumuria (mg) 16.667 ± 15.811 2.903 ±9.01 Nil 
Values in parentheses are subjects age range.   values are means (X) ± standards  deviation (S.D)  
FBS= fasting blood sugar; CCL= Creatinine clearance;  * Significantly  different from control using t- test (P<0.05)   
 
The measurement of urinary albumin loss and 
creatinine clearance or serum creatinine are the best 
screening  tests for diabetic nephropathy  and the 
overall risk of developing diabetic nephropathy varies 
between about 10% of type II diabetics to about 30% of 
types I diabetics (Akinsola et al., 1989). In type I 
diabetic, hyperglycaemia starts in the first decade of life 
and is the only recognized cause of nephropathy. On 
the contrary, in type II diabetics hyperglycemia starts 
after the forties, usually when the kidneys have already 
suffered the long term consequences of aging, and of 
other recognized promoters of chronic renal injury such 
as arterial hypertension, obesity, dyslipidaemia, and 
smoking (Ruggenet and Rumuzzi 1998). Both type I 
and type II diabetes have significantly higher fasting 
blood sugar levels than in control; i.e. there is 
significant (P < 0.05) difference between the type I and 
type II diabetics and control (Table 1). This finding is 
typical of diabetics and may be due to destruction of the 
β–cells of the pancrease by the viruses or as a result of 
autoimmune destruction, accompanied by antibodies 
directed against insulin or islet cells. These lead to 
hyperglycaemia, and as a result, there is no insulin 
secretion i.e. in type I diabetic but in type II diabetes is 
as a results of post receptors lesion or masking of the 
insulin receptors by fat which lead to reduction in the 
glucose uptakes by the cells. 
 
Microalbuminuria occurs in both type I and type II 
diabetics (Table 1). When microalbuminuric subjects 
were compared with type I diabetic and control, a 
significant (P<0.05) difference was observed. On the 
other hand, no significant (P<0.05) difference was 
observed between type II diabetic and control. This 
indicates the type I are more susceptible to 
mircoalbuminuria or diabetic nephropathy than in type II 
diabetics. The earliest detectable change in the course 
of diabetic nephropathy is thickening in the glomerulus 
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as a result of hyperglycaemia (Mogensen and 
Christensen 1984). Creatinine is a waste product in the 
blood created by the normal break down of muscles 
cells during activity. Healthy kidney filters creatinine out 
of the blood and into the urine. When kidneys are not 
working well, creatinine levels builds up in the blood. 
Creatinine clearance is the rate at which creatinine is 
been cleared in the blood i.e is been excreted into the 
urine and in the case of normal kidneys have higher  
filtration rate than the affected ones in terms of kidney 
disease (Bazari 2007). Thus, Table 1 shows that there 
is significant (P<0.05) difference between type I 
diabetics subjects and control in term of creatinine 
clearances. Creatinine clearance in type I diabetic 
subjects is low when compared to control and may lead 
to kidney failure (Mogensen and Christensen 1984). 
 
Most of the type II diabetics are hypertensive which is 
due to the deposition of fats in the heart arteries 
(artheriosclerosis) thereby causing increase in blood 
pressure. As seen in Table 1, there is significantly (P< 
0.05) higher in systolic pressure in the type II diabetic 
subjects than in control.  
Table 1 shows that there is no significant (P>0.05) 
difference between type I diabetics and control on the 
following parameters; age, weight, systolic and diastolic 
pressure. More intensive measures to restore 
normoglycaemia, normatension and decreasing the 
incidence of nephropathy in diabetic have to be 
considered.  
 
An important measure in the prevention and 
management of diabetic mellitus and diabetic 
nephropathy is tight glycaemic control. Insulin therapy 
in types I is used to reduce the risk of type I diabetes 
while in type II some hypoglycaemic drugs are used in 
the management of type II diabetes, examples of those 
drugs are suphonylurea drugs, such as tolbutamide or 
glibenclamide, can stimulate insulin secretion. While in 
the case of microalbuminuria or diabetic  nephropathy , 
calcium channel blockers, angiotensin II blocking 
agents are used in the prevention and management of 
diabetic nephropathy (Martins and Daria 2006). 
 
 
Table 2: Contingency Table Analysis of Association of Microalbuminuria with Type I a and Type II Diabetics 










No. of patients 5 4 9  3 28 31 
No Disease 0 8 8  0 8 8 
Total 5 12 17  3 36 39 
 
CONCLUSION 
The study revealed high level of glucose and reduced 
rate of creatinine clearance in type I diabetic mellitus 
than in normal subjects. Microalbuminuria which is the 
earliest laboratory evidence of diabetics nephropathy, is 
common in type I diabetes. Serum glucose levels, 
creatinine clearance and microalbuminuria are markers 
of diabetic nephropathy in the study population. 
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